BridgeBio Pharma: Barclays sees 103% price potential after FDA approval of the drug Attruby
Reading Time: 3 minutes
BridgeBio Pharma (BBIO) is experiencing enormous momentum in spring 2026, driven significantly by recent clinical and regulatory successes. A critical breakthrough was the successful FDA approval of the drug Attruby (Acoramidis) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), which sustainably strengthens the company’s commercial portfolio. Latest study data and publications from the first quarter compellingly demonstrate that the product significantly reduces the risk of overall mortality and cardiovascular-related hospitalizations...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
